Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab in Refractory, EGFR-Negative Metastatic Colorectal Carcinoma
NCT00083720Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2004
- Primary completion
- Apr 2008
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of KL-140 in colorectal cancer (CRC), sponsored by Eli Lilly and Company. Primary endpoints: Percentage of Participants With an Overall Response, Number of Participants With Adverse Events and 1 more. Started Oct 2004; status: completed.
02
Drugs
KL-140
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT00083720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00083720.